Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Jessup Website

John M. Jessup, M.D.

Selected Publications

1)  Parkinson DR, McCormack RT, Keating SM, Gutman SI, Hamilton SR, Mansfield EA, Piper MA, Deverka P, Frueh FW, Jessup JM, McShane LM, Tunis SR, Sigman CC, Kelloff GJ.
Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer.
Clin. Cancer Res. 20: 1428-44, 2014.
[Journal]
2)  Williams PM, Lively TG, Jessup JM, Conley BA.
Bridging the gap: moving predictive and prognostic assays from research to clinical use.
Clin. Cancer Res. 18: 1531-9, 2012.
[Journal]
3)  Meshinchi S, Hunger SP, Aplenc R, Adamson PC, Jessup JM.
Lessons learned from the investigational device exemption review of Children's Oncology Group trial AAML1031.
Clin. Cancer Res. 18: 1547-54, 2012.
[Journal]
4)  Poste G, Carbone DP, Parkinson DR, Verweij J, Hewitt SM, Jessup JM.
Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development.
Clin. Cancer Res. 18: 1515-23, 2012.
[Journal]
5)  Zhang J, Espinoza LA, Kinders RJ, Lawrence SM, Pfister TD, Zhou M, Veenstra TD, Thorgeirsson SS, Jessup JM.
NANOG modulates stemness in human colorectal cancer.
Oncogene. [Epub ahead of print], 2012.
[Journal]
6)  Zwart SR, Jessup JM, Ji J, Smith SM.
Saturation diving alters folate status and biomarkers of DNA damage and repair.
PLoS ONE. 7: e31058, 2012.
[Journal]
7)  Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, Stemmermann GN, Blanke CD, Macdonald JS.
Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection.
J. Clin. Oncol. 30: 2327-33, 2012.
[Journal]
8)  Jessup J, Gunderson L, Compton C.
Colon And Rectum. In: AJCC Cancer Staging Manual. Volume 7th Edition.
New York: Springer; 2010. p. 143-164 [Book Chapter]
9)  Sobin LH, Compton CA, Gospodarowicz M, Greene FL, Gunderson LL, Jessup JM, Wittekind C.
'Evidence-based medicine: the time has come to set standards for staging'. Is a radical overhaul really needed?.
J. Pathol. 221: 361-2, 2010.
[Journal]
10)  Dancey JE, Dobbin KK, Groshen S, Jessup JM, Hruszkewycz AH, Koehler M, Parchment R, Ratain MJ, Shankar LK, Stadler WM, True LD, Gravell A, Grever MR.
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
Clin. Cancer Res. 16: 1745-55, 2010.
[Journal]
11)  Washington MK, Berlin J, Branton PA, Burgart LJ, Carter DK, Compton CC, Fitzgibbons PL, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE, Vauthey JN.
Protocol for the examination of specimens from patients with carcinoma of the distal extrahepatic bile ducts.
Arch. Pathol. Lab. Med. 134: e8-13, 2010.
[Journal]
12)  Washington MK, Berlin J, Branton PA, Burgart LJ, Carter DK, Compton CC, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE, Vauthey JN.
Protocol for the examination of specimens from patients with carcinoma of the intrahepatic bile ducts.
Arch. Pathol. Lab. Med. 134: e14-8, 2010.
[Journal]
13)  Washington MK, Berlin J, Branton PA, Burgart LJ, Carter DK, Compton CC, Fitzgibbons PL, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE, Vauthey JN.
Protocol for the examination of specimens from patients with carcinoma of the perihilar bile ducts.
Arch. Pathol. Lab. Med. 134: e19-24, 2010.
[Journal]
14)  Washington MK, Tang LH, Berlin J, Branton PA, Burgart LJ, Carter DK, Compton CC, Fitzgibbons PL, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE.
Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the appendix.
Arch. Pathol. Lab. Med. 134: 171-5, 2010.
[Journal]
15)  Washington MK, Tang LH, Berlin J, Branton PA, Burgart LJ, Carter DK, Compton CC, Fitzgibbons PL, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE.
Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the colon and rectum.
Arch. Pathol. Lab. Med. 134: 176-80, 2010.
[Journal]
16)  Washington MK, Tang LH, Berlin J, Branton PA, Burgart LJ, Carter DK, Compton CC, Fitzgibbons PL, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE.
Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the small intestine and ampulla.
Arch. Pathol. Lab. Med. 134: 181-6, 2010.
[Journal]
17)  Washington MK, Tang LH, Berlin J, Branton PA, Burgart LJ, Carter DK, Compton CC, Fitzgibbons PL, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE.
Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the stomach.
Arch. Pathol. Lab. Med. 134: 187-91, 2010.
[Journal]
18)  Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK.
Revised TN categorization for colon cancer based on national survival outcomes data.
J. Clin. Oncol. 28: 264-71, 2010.
[Journal]
19)  Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart A.
Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes.
J. Clin. Oncol. 28: 256-63, 2010.
[Journal]
20)  Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL.
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy.
J. Clin. Oncol. [Epub ahead of print], 2009.
[Journal]
21)  Kelloff GJ, Choyke P, Coffey DS.
Challenges in clinical prostate cancer: role of imaging.
AJR Am J Roentgenol. 192: 1455-70, 2009.
[Journal]
22)  Lin L, Amin R, Gallicano GI, Glasgow E, Jogunoori W, Jessup JM, Zasloff M, Marshall JL, Shetty K, Johnson L, Mishra L, He AR.
The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling.
Oncogene. [Epub ahead of print], 2009.
[Journal]
23)  Laguinge LM, Samara RN, Wang W, El-Deiry WS, Corner G, Augenlicht L, Mishra L, Jessup JM.
DR5 receptor mediates anoikis in human colorectal carcinoma cell lines.
Cancer Res. 68: 909-17, 2008.
[Journal]
24)  Tang Y, Kitisin K, Jogunoori W, Li C, Deng CX, Mueller SC, Ressom HW, Rashid A, He AR, Mendelson JS, Jessup JM, Shetty K, Zasloff M, Mishra B, Reddy EP, Johnson L, Mishra L.
Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling.
Proc. Natl. Acad. Sci. U.S.A. 105: 2445-50, 2008.
[Journal]
25)  Washington MK, Berlin J, Branton PA, Burgart LJ, Carter DK, Fitzgibbons PL, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE, Compton CC.
Protocol for the examination of specimens from patients with primary carcinomas of the colon and rectum.
Arch. Pathol. Lab. Med. 132: 1182-93, 2008.
[Journal]
26)  Samara RN, Laguinge LM, Jessup JM.
Carcinoembryonic antigen inhibits anoikis in colorectal carcinoma cells by interfering with TRAIL-R2 (DR5) signaling.
Cancer Res. 67: 4774-82, 2007.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 5/2/2014.